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Abstract
Background—Classification of breast cancer into intrinsic subtypes has clinical and 
epidemiologic importance. To examine accuracy of immunohistochemistry (IHC)-based methods 
for identifying intrinsic subtypes, a three-biomarker IHC panel was compared to the clinical 
record and RNA-based intrinsic (PAM50) subtypes.
Methods—Automated scoring of estrogen receptor (ER), progesterone receptor (PR) and HER2 
was performed on IHC-stained tissue microarrays (TMAs) comprising 1,920 cases from the 
African American Breast Cancer Epidemiology and Risk (AMBER) consortium. Multiple cores 
(1–6/case) were collapsed to classify cases, and automated scoring was compared to the clinical 
record and to RNA-based subtyping.
Results—Automated analysis of the three-biomarker IHC panel produced high agreement with 
the clinical record (93% for ER and HER2, and 88% for PR). Cases with low tumor cellularity and 
smaller core size had reduced agreement with the clinical record. IHC-based definitions had high 
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agreement with the clinical record regardless of hormone receptor positivity threshold (1% vs. 
10%), but a 10% threshold produced highest agreement with RNA-based intrinsic subtypes. Using 
a 10% threshold, IHC-based definitions identified the basal-like intrinsic subtype with high 
sensitivity (86%), while sensitivity was lower for luminal A, luminal B and HER2-enriched 
subtypes (76%, 40% and 37%, respectively).
Conclusion—Three-biomarker IHC-based subtyping has reasonable accuracy for distinguishing 
basal-like from non-basal-like, while additional biomarkers are required for accurate classification 
of luminal A, luminal B and HER2-enriched cancers.
Impact—Epidemiologic studies relying on three-biomarker IHC status for subtype classification 
should use caution when distinguishing luminal A from luminal B and when interpreting findings 
for HER2-enriched cancers.
Keywords
automated digital pathology; breast cancer; estrogen receptor; HER2; immunohistochemistry; 
intrinsic subtype; molecular pathologic epidemiology; PAM50; progesterone receptor
Introduction
Breast cancer is a heterogeneous disease, comprised of distinct tumor subtypes [1]. While 
some epidemiologic studies have used additional markers or assays to define etiologic 
subtypes [2–4], the majority relied on estrogen receptor (ER), progesterone receptor (PR) 
and HER2 to classify breast cancers as hormone receptor (HR) positive, HER2-positive or 
triple negative [5–8]. These studies have identified heterogeneity in breast cancer etiology, 
but some lack of agreement between studies may be attributable to discordant subtype 
classification. Few studies have systematically compared immunohistochemical (IHC), 
clinical record and RNA-based intrinsic subtypes to estimate classification accuracy, 
particularly using tissue microarrays (TMAs) [9, 10].
The advent of automated methods to analyze digital pathology data has begun to support 
high-throughput IHC-based breast cancer subtyping in large epidemiologic studies [11]. 
Simultaneously, RNA-based methods have become more readily available for application in 
formalin-fixed paraffin-embedded (FFPE) tissues [12]. In the present study, we carried out 
IHC staining for ER, PR and HER2 using TMAs containing multiple cores per case for each 
of 1,920 cases in the African American Breast Cancer Epidemiology and Risk (AMBER) 
consortium. Herein, we describe 1) automated digital quantification of this three biomarker 
IHC panel, 2) methods for core-to-case collapsing, and 3) IHC-based agreement with 
clinical scoring in the medical record. Finally, treating PAM50 as the reference standard for 
the purposes of the present analysis, we evaluate 4) agreement between three biomarker 
IHC-based subtype classification and RNA-based PAM50 intrinsic subtyping. While earlier 
studies employed a 10% threshold [13–15], current clinical guidelines recommend a 1% 
threshold for defining ER and PR positivity status [16], and we evaluate the impact of this 
revised threshold on agreement between IHC-based and RNA-based intrinsic subtyping.
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Materials and Methods
Study population and tissue microarray construction
The African American Breast Cancer Epidemiology and Risk (AMBER) consortium is 
comprised of observational studies of breast cancer in African American women [17]. The 
present study includes 1,920 cases within the AMBER consortium for which paraffin-
embedded tissue was available in tissue microarrays (TMAs). Cases were from the Carolina 
Breast Cancer Study Phase 3 (CBCS; n=599), the Black Women’s Health Study (BWHS; 
n=199), and the Women’s Circle of Health Study (WCHS; n=309). In addition, we included 
645 non-AA cases from CBCS and 168 non-AA cases from WCHS (Table 1) as these cases 
were present on the same TMAs and were relevant to our evaluation of subtype 
classification rates. Clinical ER, PR and HER2 status were abstracted from medical records. 
Tumor grade was centrally assigned for CBCS cases by a single pathologist (JG) using the 
Nottingham breast cancer grading system [18]. Each study was approved by Institutional 
Review Boards at participating hospitals and academic institutions.
Paraffin-embedded tumor blocks were requested from participating pathology laboratories 
for each case. Study pathologists (JG, HH, TK) marked hematoxylin & eosin (H&E)-stained 
slides to indicate areas enriched for invasive breast cancer for coring, and TMA construction 
and sectioning were carried out at the Translational Pathology Lab (TPL), University of 
North Carolina at Chapel Hill (UNC) for CBCS and at Roswell Park Cancer Institute (RPCI) 
for BWHS & WCHS. TMA blocks included between one and four tumor cores per case 
measuring 1.0 mm (CBCS), or between one and six tumor cores per case measuring 0.6 mm 
in diameter (BWHS and WCHS; Table 1). For CBCS, top and bottom sections from blocks 
containing a total of 4783 cores were stained with H&E and examined by study pathologists 
(JG or LT) for presence of tumor cells, and 503 cores (11%) lacking sufficient tumor 
cellularity (<50 tumor nuclei per core) were excluded from analyses. For TMA blocks not 
manually evaluated for tumor cellularity (BWHS and WCHS), digital analysis of IHC was 
used to eliminate cores lacking sufficient tumor cellularity (<50 tumor nuclei per core) and, 
of a total of 2060 cores, 290 (14%) were excluded due to low tumor cellularity.
Immunohistochemistry and RNA-based assays
TMA blocks were cut into 5 µM serial sections and IHC staining protocols were optimized 
under pathologist supervision to achieve the best possible agreement with the clinical record. 
Final conditions were independently reviewed by multiple pathologists. Detailed IHC 
methods are described in Supplementary Materials and Methods.
Nanostring assays were used to measure the PAM50 gene signature on 535 cases from 
CBCS. Two cores from the same tumor block used for TMA construction were randomly 
sampled and pooled for analysis. The areas surrounding the holes left by the cores were 
examined by a study pathologist (JG or LT) to confirm the presence of tumor cells in the 
cores used for RNA extraction. RNA was isolated using the RNeasy FFPE kit from Qiagen 
and Nanostring analyses were performed in the Rapid Adoption Molecular (RAM) 
laboratory at UNC. Nanostring probe sets included 200 genes of which 50 were the PAM50 
genes [19] and five were housekeeping genes. Gene expression was median-centered and 
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samples were standardized to zero mean and unit variance. The NanoStringNorm package in 
Bioconductor was used to eliminate samples that did not have sufficient nanostring data 
quality (n=43) and the PAM50 predictor was performed as previously described [19] to 
categorize breast tumors into five intrinsic subtypes (luminal A, luminal B, HER2-enriched, 
basal-like, normal-like). Tumors classified as normal-like may result from extensive normal 
epithelial or stromal content in the tumor [20], so we excluded normal-like tumors (n=29) 
from our analysis. We also excluded 16 cases with equivocal HER2 IHC status, as we could 
not assess IHC-based subtype, giving rise to 447 cases with both IHC and intrinsic 
subtyping data.
Automated digital quantification of a three biomarker IHC-based panel
Automated digital image analysis of IHC staining (Figure 1) was performed using a Genie 
classifier and the Nuclear v9 algorithm (for ER and PR) or Membrane v9 algorithm (for 
HER2; Aperio Technologies, Vista, CA), and is described in more detail in Supplementary 
Materials and Methods.
To validate automated analyses, study pathologists (JG, HH, TK) carried out manual 
reviews of IHC staining within a training set of TMAs. For ER and PR, individual cores 
were classified as negative (<1% positive), borderline (≥1% and <10%) or positive (≥10%). 
For HER2, individual cores were classified as negative (0/1+), positive (3+) or equivocal 
(2+) [21]. Using a 10% threshold to define ER and PR status, agreement between automated 
and manual scoring was 89% for ER and 91% for PR (Supplementary Table S1). After 
excluding cores with equivocal HER2 (2+) status in either the TMA or clinical record 
(n=63), HER2 status agreement between automated and manual scoring was 93%. As 
expected, agreement was slightly lower with additional categories [ER and PR status as 
negative (<1%), borderline (1–10%) or positive (≥10%), HER2 status as negative (0/1+), 
equivocal (2+) or positive (3+), Supplementary Table S1].
Core-to-case collapsing
We tested two core-to-case collapsing methods to define a single ER, PR and HER2 status 
for each case. The first assigned case-level status using a tumor cellularity-weighted 
approach. The weighted average of percent positivity was calculated by summing the 
product of percent positivity and core weight across all cores per case. Core weight was 
defined as the number of tumor nuclei in a given core divided by the total number of tumor 
nuclei across all cores for that case. Thresholds for ER, PR (≥1% and ≥10%) and HER2 
(≥10%) positivity were subsequently applied to define a dichotomous status for each of 
these three markers. Tumor cells staining positive at any intensity were considered positive 
for ER and PR, while only tumor cells staining at the 3+ level were considered positive for 
HER2. Equivocal (2+) HER2 status was defined as <10% of tumor cells staining at the 3+ 
level and ≥10% of tumor cells staining at the 2+ level, while negative HER2 status included 
all other cases. The 10% threshold for HER2 was optimized to agree with manual scoring 
performed according to the then-current HER2 guidelines, indicating that a 30% threshold 
should be used for HER2 [21]. The second core-to-case collapsing method classified the 
case as ER, PR or HER2 positive if any core was positive for ER, PR or HER2, respectively. 
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Core-level ER and PR positivity was defined considering both ≥1% and ≥10% thresholds, 
while HER2 positivity was defined as ≥10% of cells staining at the 3+ intensity level.
IHC-based agreement with clinical scoring in the medical record
Kappa statistics were used to examine case-level agreement between TMA and clinical ER, 
PR and HER2 status in the medical record [22]. Given that the majority of cases (76%) were 
diagnosed prior to ASCO guidelines recommending the use of a 1% threshold for 
classification of HR positivity [16], our primary analysis of case-level agreement between 
TMA and clinical ER, PR and HER2 status was conducted using a 10% threshold to define 
HR positivity status. Analyses were stratified by core-to-case collapsing method in addition 
to core diameter and median cellularity, in order to determine the impact of these factors on 
agreement with the clinical record. We conducted sensitivity analyses using a 1% threshold 
for ER and PR, and excluding cases with only one core.
Agreement between IHC-based and RNA-based subtyping
Using case-level ER, PR and HER2 status, we defined IHC-based subtypes as follows: ER 
or PR positive, HER2 negative (luminal A); ER or PR positive, HER2 positive (luminal B); 
ER and PR negative, HER2 positive (HER2-enriched); ER and PR and HER2 negative 
(basal-like). We also defined IHC-based subtypes using a PR cut point of 20% [23]; ER 
positive or PR>20%, HER2 negative (luminal A); ER or PR positive, HER2 positive or ER 
or PR≤20%, HER2 negative (luminal B). In the absence of Ki67 data, tumor grade may 
distinguish luminal A and HER2-negative luminal B cancers [24], and we explored 
combined grade as follows; ER positive or PR>20%, combined grade I or II, HER2 negative 
(luminal A); ER or PR positive, HER2 positive or ER or PR≤20% or combined grade III, 
HER2 negative (luminal B). Dichotomizing combined grade as I vs. II/III reduced subtype 
classification accuracy, and mitotic grade offered no classification advantages over 
combined grade and therefore these results are not presented. Finally, we defined HER2-
enriched cases as ER negative, HER2 positive, regardless of PR status. Cases with equivocal 
HER2 status remained unclassified and were excluded from subsequent analyses. We 
examined the impact of using 1% and 10% thresholds to define ER and PR status on the 
sensitivity [(true positives/(true positives + false negatives)], specificity [true negatives/(true 
negatives + false positives)], and accuracy [(true positives + true negatives)/total] of TMA 
IHC subtyping with respect to intrinsic subtyping for a subset of cases (n=447).
Statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC) and 
STATA version 13.0 (Stata Corp., College Station, TX).
Results
IHC-based agreement with the clinical record: impact of core-to-case collapsing method
Using the weighted core-to-case collapsing method to define HR positivity status, agreement 
with the clinical record was 93% for ER and 88% for PR (using a ≥10% threshold; Table 2). 
These results were not impacted by a 1% positivity threshold (data not shown), nor was 
agreement substantially altered when using the any positive core-to-case collapsing method 
(Table 2). However, the any positive method with a 1% threshold resulted in reduced 
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agreement with the clinical record (90% agreement for ER, 85% for PR). As such, we chose 
to proceed with the weighted method and 10% threshold to maximize agreement with 
clinical laboratory data for defining ER and PR positivity in our population.
For HER2, agreement rates were similar for weighted and any positive methods (95% and 
93%, respectively; Table 3). In addition, while both methods had high specificity (95% and 
98% for any positive and weighted methods, respectively), the any positive method had 
higher sensitivity for identifying HER2 positive cases (82% vs. 75%, respectively). 
However, the any positive method produced a higher number of equivocal (2+) cases, 
relative to the weighted method (Table 3). A hybrid of both core-to-case collapsing methods, 
defining HER2 status based on being positive by either the weighted or any positive method, 
maximized sensitivity (78%) and minimized the number of equivocal cases, while 
maintaining similar levels of agreement with the clinical record (Table 3). Moreover, the 
number of equivocal cases using the hybrid method (n=74; 4%) was similar to that of the 
clinical record (n=50; 3%). As such, we chose to proceed with this hybrid method to define 
HER2 status.
For all three biomarkers, agreement between automated analysis of TMAs and the clinical 
record was similar to agreement rates reported between automated analysis of TMAs and 
manual review (Supplementary Table S1).
IHC-based agreement with the clinical record: impact of TMA characteristics
Core cellularity and diameter impacted agreement rates between TMAs and the clinical 
record. Using a 10% threshold to define HR positivity, cases with high tumor cellularity had 
higher agreement with the clinical record for ER and PR, as shown in Table 4. Similarly, 
cases with larger cores had higher ER agreement and PR agreement (Table 4). However, 
neither core cellularity nor diameter substantially impacted agreement with the clinical 
record for HER2, with similar agreement rates for tumors with high and low cellularity, and 
for 1.0 mm and 0.6 mm cores (Table 4). Using a 1% threshold to define ER and PR status 
did not alter agreement rates for cores with high cellularity and 1.0 mm diameter, but 
improved agreement for cores with low cellularity and 0.6 mm diameter (data not shown). 
Excluding cases with only one core (7% of cases) did not impact our findings (data not 
shown).
Agreement between IHC-based and RNA-based PAM50 intrinsic subtyping
For the subset of CBCS cases with intrinsic subtyping data (n=447), agreement between 
three biomarker IHC and RNA-based subtypes is shown in Table 5. Given recent changes in 
clinical thresholds for ER and PR positivity [16], both 1% and 10% thresholds were 
considered to assess agreement. While IHC-based definitions of luminal A (ER or PR 
positive and HER2 negative) and luminal B (ER or PR positive and HER2 positive) resulted 
in high sensitivity for identifying luminal A tumors, specificity was low for both 1% and 
10% thresholds. Conversely, luminal B specificity was high but sensitivity was low, 
regardless of threshold (Supplementary Table S2). Work by Prat and colleagues [25], 
reflected in St. Gallen guidelines [23], indicated that cases with negative HER2 status but 
low (≤20%) PR positivity should be classified as luminal B, as an additional means of 
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distinguishing luminal A from luminal B. Using this definition, the 10% ER threshold 
yielded greatest accuracy (Table 5). St Gallen guidelines also suggest that Ki67 expression 
may distinguish luminal A and HER2-negative luminal B disease [23]. Given that we lacked 
Ki67 data, we explored tumor grade as a surrogate [24]. Overall, gains in sensitivity were 
offset by losses in specificity and vice versa, and accuracy was substantively unchanged 
(~70–80%) regardless of grade (Supplementary Table S3).
HER2-enriched cases identified by RNA-based PAM50 analysis were difficult to accurately 
identify by IHC. Defining HER2-enriched cases as ER and PR negative, HER2 positive 
resulted in low sensitivity, although specificity was high (Supplementary Table S2). We 
found that defining HER2-enriched cases as ER negative and HER2 positive, regardless of 
PR status, resulted in slightly improved agreement with the intrinsic HER2-enriched subtype 
(Table 5). Using a 10% threshold, we found that 26% of HER2-enriched cases identified by 
RNA-based intrinsic subtyping were classified as luminal B by IHC, while the use of a 1% 
threshold gave rise to 43% of HER2-enriched cases identified by RNA-based intrinsic 
subtyping which were classified as luminal B by IHC (Table 5). Finally, utilization of 
clinical HER2 status (which includes ISH data) to identify HER2-enriched cases did not 
improve on agreement rates observed using TMA HER2 status (data not shown).
Triple negative status (ER, PR and HER2 negative) using the three biomarker IHC panel had 
relatively high accuracy for identifying the basal-like intrinsic subtype (Table 5). At the 10% 
threshold, we found that 10% of basal-like cases identified by RNA-based intrinsic 
subtyping were classified as luminal A or B by IHC (Table 5). However, rates of discordant 
classification between IHC and RNA-based intrinsic subtyping were higher at the 1% 
threshold, with 27% of basal-like cases identified by RNA-based intrinsic subtyping 
classified as luminal A or B by IHC (Table 5). Including normal-like intrinsic cases (n=26 
with complete IHC data) in our comparisons between three biomarker IHC and RNA-based 
subtypes did not alter our findings (data not shown).
Discussion
In this consortium comprising three large epidemiologic studies, we found that classification 
of ER, PR and HER2 status using automated digital pathology resulted in high agreement 
with the clinical record for all three biomarkers. Agreement rates were highest when using a 
tumor cellularity-weighted method for core-to-case collapsing and in cases with high tumor 
cellularity. Furthermore, we report that this three biomarker IHC-based panel conferred high 
sensitivity and specificity for identifying tumors classified as basal-like using RNA-based 
intrinsic subtyping. However, our findings highlight the need for further optimization of 
methods to identify HER2-enriched breast cancers and to discriminate between luminal A 
and B cancers, likely through inclusion of new biomarkers like Ki67 and/or other 
biomarkers uniquely present in luminal B or HER2-enriched tumors. As such, we 
recommend that epidemiologic studies relying on ER, PR and HER2 IHC status for subtype 
classification use caution when distinguishing luminal A from luminal B cancers and when 
interpreting findings for HER2-enriched cancers.
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The advent of digital pathology carries potential to advance molecular epidemiologic 
pathology research by providing a platform to obtain high-throughput and high-resolution 
quantitative data. Previous studies based on tumor-bank series have shown that inter-
laboratory agreement rates for ER and PR range from 80–90% [26–28]. Our findings from 
this consortium, which drew from multiple clinical centers across the United States, showed 
that agreement rates were on the high end of this range for both biomarkers, thereby 
providing validation for digital IHC subtyping methods in epidemiologic research. 
Furthermore, our agreement rates for HER2 exceeded previously published inter-laboratory 
agreement rates of ~80% for IHC HER2 staining [29]. These findings may reflect 
improvements over time in IHC methods, improved efforts to ensure antigen stability, and 
other methodological strengths of our work.
While technical factors have been demonstrated to play a role [27, 30, 31], tumor biology 
and molecular factors may also drive discordance in biomarker classification. We and others 
[26, 28] have shown that PR agreement is often lower than that of ER, potentially due to 
more heterogeneous expression within a given tumor, or intratumoral heterogeneity. 
Intratumoral heterogeneity would be expected to pose a greater classification problem for 
cores representing a smaller sample of the tumor (as reflected by lower tumor cellularity 
and/or smaller core diameter); indeed, our findings suggest that agreement rates were lowest 
for PR. This explanation seems less likely to explain HER2 discordance, as neither core size 
nor cellularity was associated with agreement between TMAs and the clinical record. As 
such, intratumoral heterogeneity, in addition to technical factors including TMA 
characteristics, may contribute to the level of agreement between central and clinical 
biomarker classification.
Recent clinical guidelines have lowered the threshold used to define ER and PR positivity 
from 10% to 1%, given evidence that cases with borderline (≥1–<10%) ER and PR 
positivity derive a benefit from endocrine therapy [16]. However, subtype distribution 
within these borderline cases, comprising approximately 6% of total breast cancer cases, is 
not well understood. One study indicated that approximately one quarter of ER borderline 
cases are luminal, while up to half are basal-like [32]. This is in general agreement with our 
findings that 25% of ER borderlines were luminal, and 38% were basal-like. Conversely, 
another study reported higher prevalence of luminals (44%) and lower prevalence of basal-
likes (18%) among ER or PR borderline cases [33], suggesting that biological characteristics 
of the borderline group may vary across study populations or according to technical 
methods. We report that IHC-based surrogate definitions of PAM50 intrinsic subtypes were 
impacted by the threshold for defining ER and PR positivity, with a 1% threshold resulting 
in a greater proportion of basal-like cases classified as luminal A and B by IHC, and of 
HER2-enriched cases classified as luminal B by IHC, relative to the 10% threshold. Given 
the heterogeneity of borderline breast cancers, additional studies should refine classification 
for this group of tumors. Nonetheless, these findings demonstrate that changing clinical 
guidelines for HR positivity may adversely affect the accuracy of intrinsic subtype 
classification using a three biomarker IHC panel, potentially impacting the stability of 
epidemiologic findings over time.
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While it has been proposed that additional biomarkers such as Ki67 are required to 
accurately identify luminal A and luminal B cancers, these data are not commonly available 
in population-based studies. In the absence of Ki67, tumor grade and quantitative PR 
expression may be useful in distinguishing luminal A and luminal B cancers [23, 24]. 
However, we found that maximal accuracy was ~80% for luminal A cases and ~75% for 
luminal B cases with the inclusion of these variables, suggesting that grade and PR 
thresholds are inadequate to accurately distinguish luminal subtypes. IHC is the most 
commonly-used method for clinical classification of HER2-positive tumors, but even with 
inclusion of clinically ISH-positive cases in our HER2-enriched group, the sensitivity of the 
three biomarker IHC panel was low for identifying RNA-based HER2-enriched cases. It is 
well known that amplification or over-expression of an oncogenic pathway can occur via 
multiple molecular events, and a single marker cannot always accurately detect defects in a 
pathway. This molecular heterogeneity may contribute to discordance between the three 
biomarker IHC-based panel and the multi-gene RNA-based panel to identify HER2 pathway 
enrichment. Thus, both molecular and intratumoral heterogeneity may add to technical 
factors in producing discordance between central and clinical analyses of tumor subtype. 
These data underscore that population-based studies with three biomarker IHC-based data 
should avoid making etiologic inferences about luminal A, luminal B and HER2-enriched 
intrinsic subtypes until better IHC-based subtyping methods can be identified for these 
subtypes. In contrast, high sensitivity and specificity of the three biomarker IHC panel for 
identifying basal-like breast cancers in our study suggests that additional biomarkers such as 
CK5/6 and EGFR may not be needed to classify basal-like cancers in epidemiologic studies. 
In sum, the current data suggest that a three biomarker IHC panel is able to distinguish 
between basal-like and luminal, two key etiologic subtypes [34, 35], but that finer resolution 
of intrinsic subtyping in non-basal-like cancers requires additional markers.
Our findings should be considered in the context of strengths and weaknesses of this study. 
First, although cores without invasive carcinoma were excluded based upon manual review 
of top and bottom H&E-stained sections by study pathologists, it is possible that benign 
epithelium or ductal carcinoma in situ (DCIS) was counted as invasive tumor in automated 
IHC quantification. However, high levels of agreement with the clinical record, exceeding 
that of previous studies, mitigate concerns about this potential source of bias. Second, while 
the present analysis offers insights into IHC-based surrogates for intrinsic subtyping within 
the context of a consortium of epidemiologic studies, it is important to note that this study 
represents an incomplete sample of AMBER, specifically representing those for whom we 
had TMAs. Because this sample does not represent the entire population of AMBER, it 
cannot be used to make inferences about the distribution of subtypes within the AMBER 
source population. Third, we had incomplete data on whether tumor blocks used clinically 
were the same blocks provided to our study. Thus, the biospecimens may have differed 
leading to a downward bias in the estimation of agreement between TMAs and the clinical 
record. Strengths of this study include validation of automated staining guided by multiple 
pathologists, availability of a validated RNA-based multi-gene assay for molecular 
classification of tumor subtype, and a large, diverse sample population representing African 
American and Caucasian women.
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In conclusion, we report that automated digital analysis of IHC staining for ER, PR and 
HER2 on TMAs resulted in high agreement with the clinical record, and high sensitivity and 
specificity for identifying basal-like breast cancer cases classified by RNA-based intrinsic 
subtyping. However, we report reduced sensitivity and specificity for identifying luminal A, 
luminal B, and HER2-enriched cancers using IHC-based panels, indicating that additional 
biomarkers are required for IHC-based classification of these intrinsic subtypes.
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Figure 1. Immunohistochemical staining and automated scoring of estrogen receptor (ER), 
progesterone receptor (PR), and HER2 on tissue microarrays
Representative slides staining positive for ER (A), PR (D), and HER2 (G) are shown 
alongside higher magnification insets from these same cores (B&C, E&F and H&I, 
respectively). For hormone receptors, negative nuclei are highlighted in blue, low positive in 
yellow, medium positive in orange and strongly positive in red (C for ER; F for PR). The 
nuclear algorithm was trained to recognize epithelial cell and to exclude stromal cell regions 
(shown in gray in C, F) for hormone receptor analyses. The algorithm used for HER2 
analysis evaluated DAB staining intensity in membrane regions (yellow represents 1+, 
orange represents 2+, and red represents 3+ membrane intensity), and black lines highlight 
HER2 negative cells (I). Reduction in the number of stromal cells analyzed is a built-in 
function of the membrane algorithm (see non-segmented cells in the stromal area of Panel I). 
Scale bar (for core images) = 300 µm, scale bar (for magnified images) = 100 µm.
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